The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial
Open accessAbstract
Summary: Purpose: Brivaracetam (BRV) is a novel high‐affinity synaptic vesicle protein 2 A ligand in clinical development for the treatment of epilepsy. This phase III study (N 01252; NCT 00490035) evaluated the efficacy and safety/tolerability of BRV (20, 50, and 100 mg/day) compared with placebo (PBO) in patients aged 16–70 years with uncontrolled focal seizures with/without secondary generalization, despite treatment with one to two concomitant antiepileptic drugs at a stable and optimal dosage. Methods: This was a double‐blind, randomized, placebo‐controlled trial conducted across E urope and I ndia. Eligible patients had two or more focal seizures/month for 3 months prior to screening and eight or more focal seizures during the 8‐week prospective baseline. Concomitant use of levetiracetam was limited to 20% of randomized patients. Patients were randomized (1:1:1:1) to BRV 20, 50, 100 mg/day or PBO with no up‐titration for 12 weeks, followed by down‐titration or entry into a long‐term follow‐up study. The primary efficacy end point was percent reduction over PBO in baseline‐adjusted focal seizure frequency/week over the 12‐week treatment period. Comparison of BRV with PBO was sequential to control for multiplicity (50, 100, 20 mg/day), and thus required BRV to demonstrate superiority over PBO at 50 mg/day to meet the primary efficacy end point. Secondary efficacy variables were median percent reduction from baseline in focal seizure frequency/week, ≥50% responder rate, and seizure freedom (all seizure types). Safety assessments included treatment‐emergent adverse events (TEAE s). Key Findings: Of 399 randomized patients, 398 were included in the intent‐to‐treat (ITT) and safety populations. Overall, 367 (92.2%) of 398 patients completed the study (BRV: 93.9%, 88.9%, and 94.0% for 20, 50, and 100 mg/day, respectively; PBO: 92.0%) and 345 (86.7%) of 398 patients continued into long‐term follow‐up studies (BRV: 87.9%, 82.8%, and 88.0% for 20, 50, and 100 mg/day, respectively; PBO: 88.0%). The study did not meet its primary efficacy end point based on the predefined sequential testing strategy. Indeed, percent reduction over PBO in baseline‐adjusted focal seizure frequency/week (primary efficacy analysis) was 6.8% (p = 0.239), 6.5% (p = 0.261), and 11.7% (p = 0.037) for BRV 20, 50, and 100 mg/day, respectively. Median percent reduction from baseline in focal seizure frequency/week was 30.0% (p = 0.019), 26.8% (p = 0.092), and 32.5% (p = 0.004) for BRV 20, 50, and 100 mg/day, respectively, compared with 17.0% for PBO. Responder rates (≥50%) were 27.3% (p = 0.339), 27.3% (p = 0.372), and 36.0% (p = 0.023) for BRV 20, 50, and 100 mg/day, respectively, compared with 20.0% for PBO. Complete seizure freedom was reported by 2/99, 0/99, and 4/100 patients on BRV 20, 50, and 100 mg/day, respectively, compared with 0/100 on PBO. The incidence of TEAE s was higher for BRV 20 (56/99, 56.6%), 50 (62/99, 62.6%), and 100 mg/day (63/100, 63.0%) than PBO (53/100, 53.0%); most TEAE s were mild or moderate in severity. The most frequently reported TEAE s in the BRV groups were headache, somnolence, dizziness, and fatigue. Significance: In this study of adjunctive BRV (20–100 mg/day) in adults with uncontrolled focal seizures, the primary efficacy analysis based on the 50 mg/day dose was not statistically significant. However, BRV 100 mg/day reduced baseline‐adjusted focal seizure frequency/week by 11.7% over PBO, achieving statistical significance (p = 0.037). Secondary efficacy analyses (percent reduction from baseline in focal seizure frequency/week, ≥50% responder rate) provided supportive evidence for the efficacy of BRV 100 mg/day. BRV 20–100 mg/day was well tolerated without up‐titration, with a high completion rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415
Cited by
Biologically active γ-lactams: synthesis and natural sources
Caruano, J., Muccioli, G. G., & Robiette, R. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01349j · Cited by 436
Krauss, G. L., Klein, P., Brandt, C., Lee, S. K., Milanov, I., Milovanovic, M., Steinhoff, B. J., & Kamin, M. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30399-0 · Cited by 342
Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review
Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P., & Steinhoff, B. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012021 · Cited by 288
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Metadata
- Authors
- Ryvlin, P., Werhahn, K. J., Blaszczyk, B., Johnson, M. E., & Lu, S.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2013-10-28
- Volume
- 55
- Issue
- 1
- Pages
- 47-56
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2051013481
- Cited by
- 231
- References
- 2
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/epi.12432
- The paper
- Ryvlin, P., Werhahn, K. J., Blaszczyk, B., Johnson, M. E., & Lu, S. (2014). Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial. Epilepsia. https://doi.org/10.1111/epi.12432
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.